The company behind the study hopes to complete their study evaluating the use of cannabis oil for treating chronic pain by fall 2018.
The launch of Delta™ means producers are now able to to recreate and restore the full plant terpene profile in any oil-based cannabis product.
The trial will help distinguish between multiple formulations based on various measures, including pharmacological and pharmacodynamic measures that may be predictive of drug efficacy.
Human brain imaging clinical trials are already underway for a proprietary cannabinoid formulation to treat a major condition.
The testing performed by MA Analytics will protect consumers from contaminants, chemicals, and other impurities ensuring that the end consumer is getting the best possible product.